ArticleAnnals of clinical microbiology and antimicrobials2012
Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin.
Article in Annals of clinical microbiology and antimicrobials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 166 citations in OpenAlex.
- Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials.Critical care (London, England) · 2023Trial
- Trial
- Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial.The Lancet. Respiratory medicine · 2016Trial
- Rosuvastatin for sepsis-associated acute respiratory distress syndrome.The New England journal of medicine · 2014Trial
- Statin-induced lipid carrier stress reveals a conserved vulnerability in β-lactam-resistant Gram-positive bacteria.Nature communications · 2026Article
- Comparison of the Antimicrobial Effect of Atorvastatin and Nano-Atorvastatin Mouthwash onJournal of dentistry (Shiraz, Iran) · 2026Article
- Laser-Engineered Multilayer Coatings Based on Zinc Oxide and Lovastatin-Functionalized Bioactive Glasses for Corrosion-Resistant and Antimicrobial Stainless Steel Implants.Biomimetics (Basel, Switzerland) · 2026Article
- Electrospun PVA Nanofibers Co-Loaded with Atorvastatin and Zinc Oxide for Antibacterial and In Vitro Wound Healing Applications.Biomedicines · 2026Article
- Effect of renin-angiotensin-aldosterone system inhibitor and statin medication on periodontal status of patients at risk of cardiovascular disease: a systematic review and meta-analysis.The Saudi dental journal · 2026Review
- Metabolic, enterohepatic and gut microbial effects of atorvastatin in healthy men.Endocrine connections · 2026Article
- Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Development and Optimization of Polyelectrolyte Complex Stabilized Piperine Adjuvant Simvastatin Nanoformulation for Improved Therapeutic Effect.Current pharmaceutical design · 2026Article
- New Frontiers for Old Medications: Repurposing Approved Drugs Against Gram-Negative Bacterial Infections.Microorganisms · 2025Review
- Small-molecule strategies to combat antibiotic resistance: mechanisms, modifications, and contemporary approaches.RSC advances · 2025Review
- Therapeutic potential of3 Biotech · 2025Article
- Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Statins, Allies against Antibiotic Resistance?Current medicinal chemistry · 2025Review
- Association between statin administration and outcome in patients with sepsis: A retrospective study.Open medicine (Warsaw, Poland) · 2025Article
- Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.Frontiers in immunology · 2025Article
- Baseline morbidity and chronic medications as determinants of sepsis outcomes: focus on statins, corticosteroids, and NSAIDs in a population-based cohort of 59,578 patients.Frontiers in pharmacology · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStatins have several effects beyond their well-known antihyperlipidemic activity, which include immunomodulatory, antioxidative and anticoagulant effects. In this study, we have tested the possible antimicrobial activity of statins against a range of standard bacterial strains and bacterial clinical isolates.
methodsMinimum inhibitory concentrations (MIC) values were evaluated and compared among three members of the statins drug (atorvastatin, simvastatin, and rosuvastatin).
resultsIt was revealed that statins are able to induce variable degrees of antibacterial activity with atorvastatin, and simvastatin being the more potent than rosuvastatin. Methicillin-sensitive staphylococcus aureus (MSSA), methicillin-resistant staphylococcus aureus (MRSA), vancomycin-susceptible enterococci (VSE), vancomycin-resistant enterococcus (VRE), acinetobacter baumannii, staphylococcus epidermidis, and enterobacter aerogenes, were more sensitive to both atorvastatin, and simvastatin compared to rosuvastatin. On the other hand, escherichia coli, proteus mirabilis, and enterobacter cloacae were more sensitive to atorvastatin compared to both simvastatin and rosuvastatin. Furthermore, most clinical isolates were less sensitive to statins compared to their corresponding standard strains.
conclusionOur findings might raise the possibility of a potentially important antibacterial class effect for statins especially, atorvastatin and simvastatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.